Esperion Therapeutics, Inc. (ESPR) is a publicly traded Healthcare sector company. As of May 21, 2026, ESPR trades at $3.13 with a market cap of $805.76M and a P/E ratio of -225901000000000000.00. ESPR moved +0.16% today. Year to date, ESPR is -17.85%; over the trailing twelve months it is +244.45%. Its 52-week range spans $0.69 to $4.18. Analyst consensus is neutral with an average price target of $2.92. Rallies surfaces ESPR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Esperion Sale at $3.16 Per Share Includes $100M CVRs, Faces Rights Probe: Esperion Therapeutics agreed to a $1.1B sale to Archimed at $3.16 per share plus CVRs up to $100M tied to bempedoic acid and bumetanide milestones, a 58% premium over April 30 price. Halper Sadeh LLC is probing whether the deal limits bids and grants insiders benefits not available to shareholders.
| Metric | Value |
|---|---|
| Price | $3.13 |
| Market Cap | $805.76M |
| P/E Ratio | -225901000000000000.00 |
| EPS | $-0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.18 |
| 52-Week Low | $0.69 |
| Volume | 2.14K |
| Avg Volume | 0 |
| Revenue (TTM) | $418.24M |
| Net Income | $-7.42M |
| Gross Margin | 0.00% |
7 analysts cover ESPR: 0 strong buy, 0 buy, 6 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $2.92.